Sunday, 28 February 2021

AB SCIEX launches newer version of ADME software

12 November 2014 | News | By BioSpectrum Bureau

AB SCIEX launches newer version of ADME software

The new software ensures success in high throughput drug discovery and development

The new software ensures success in high throughput drug discovery and development

AB SCIEX has introduced DiscoveryQuant 3.0 Software, a new version of its ADME software. It enables scientists to make better decisions about drug candidates faster, as the new software reduces tedious LC/MS method development time with a fast, robust, and reliable process that optimises methods for hundreds of small and/or large molecules.

The new software expedites the method development process from existing database information, automates on-column optimisation, and easily analyses and processes multiple samples at the same time. Supported on all AB SCIEX MS platforms (TripleTOF, QTRAP, and Triple Quad systems) and with the ability to seamlessly communicate with MultiQuant 3.0 Software,it ensures success in high throughput drug discovery and development.

"Discovery labs continue to search for ways to improve efficiency to address the demands of fast turn-around times required in the drug candidate screening process. Our goal is to offer best-in-class system solutions and DiscoveryQuant 3.0 software in combination with our LCMS platforms stays true to that, as it provides scientists with the ability to rapidly develop methods for all molecule types, in a high throughput environment," said Mr Joe Fox, senior director of pharma business at AB SCIEX.

The software is available online for trial and purchase.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls